Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Payables (2020 - 2025)

Lyell Immunopharma's Payables history spans 6 years, with the latest figure at $2.6 million for Q3 2025.

  • For Q3 2025, Payables fell 28.59% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $2.6 million, down 28.59%, while the annual FY2024 figure was $5.4 million, 11.4% up from the prior year.
  • Payables for Q3 2025 was $2.6 million at Lyell Immunopharma, down from $3.4 million in the prior quarter.
  • Across five years, Payables topped out at $6.5 million in Q1 2022 and bottomed at $2.6 million in Q3 2025.
  • The 5-year median for Payables is $4.3 million (2022), against an average of $4.4 million.
  • The largest annual shift saw Payables crashed 65.87% in 2021 before it surged 36.68% in 2023.
  • A 5-year view of Payables shows it stood at $3.2 million in 2021, then rose by 22.14% to $3.9 million in 2022, then increased by 22.98% to $4.8 million in 2023, then rose by 11.4% to $5.4 million in 2024, then crashed by 52.14% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Payables are $2.6 million (Q3 2025), $3.4 million (Q2 2025), and $3.7 million (Q1 2025).